CAR-T Cellular Therapy Development
CAR-T Cellular Therapy Solutions
From optimizing CAR-T cell design and evaluating pre-clinical models to discovering response biomarkers and mechanisms of action, together we can advance the field of cellular therapy and improve the human condition.
- Optimize CAR-T cell method development
- Measure metabolic fitness and persistence
- Create manufacturing acceptance criteria
- Monitor post-infusion exhaustion and toxicity
- Explore the response of the tumor microenvironment to CAR-T cells in solid tumors
- Measure changes in the solid tumor microenvironment
- Quantify CAR-T cell exhaustion
- Understand mechanisms of immune cell exhaustion
- Discover biomarkers for exhaustion
- Develop treatments to prevent or reverse immune cell exhaustion
- Spatially evaluate pre-clinical solid tumor models
- Visualize CAR-T cell trafficking within the tumor microenvironment
- Discover biomarkers for responders/non-responders
Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach.
Simple Summary: This review summarizes gene-expression profiling insights into the background and origination of diffuse large B-cell lymphomas (DLBCL). To further unravel the molecular biology of these lymphomas, a consortium panel called BLYM-777 was designed including genes important for subtype classifications, genetic pathways, tumor-microenvironment, immune response and resistance to targeted therapies.
Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies.
Despite the high rates of complete remission following chimeric antigen receptor (CAR) T cell therapy, its full capacity is currently limited by the generation of dysfunctional CAR T cells. Senescent or exhausted CAR T cells possess poor targeting and effector functions, as well as impaired cell proliferation and persistence in vivo.
PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.
Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the immunosuppressive tumor microenvironment (TME), characterized by high levels of multiple inhibitory factors, including transforming growth factor (TGF)-beta.